CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

CRISPR Therapeutics AG

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026

$50.04+0.79 (+1.60%)

Close on Oct 19, 2026

Market cap: $4.83B
P/E (TTM): –
Dividend yield: –

CRISPR Therapeutics AG income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	3.51	37	371	1.20	915	0.72	290	3.12	41	5.16	0.25	–
Research & Development	285	310	387	462	341	221	179	114	70	42	13	1.51
General & Administrative	74	73	76	102	100	86	63	48	36	31	13	5.11
Operating Expenses	668	504	594	674	541	355	243	162	106	73	26	6.63
Operating Income	-665	-467	-223	-673	374	-354	47	-159	-65	-68	-26	-6.63
Interest & Investment Income	–	104	76	23	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	–	–	–	–	-5.47	-4.28	-1.76	-37	–	–
Other Non-Operating Income	87	104	72	23	6.00	6.38	21	-5.49	-1.96	45	-0.09	-0.24
Asset Impairment Charges	–	–	–	–	–	–	–	0	0	0	0	0
Pretax Income	-578	-363	-151	-651	380	-348	67	-164	-67	-23	-26	-6.86
Income Tax Expense	3.63	3.59	2.89	-0.33	1.87	0.81	0.45	0.55	1.75	0.48	0.01	-0.06
Net Income incl. Noncontrolling Interests	-582	-366	-154	-650	378	-349	67	-165	-68	-23	-26	-6.80
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	-0.03	-0.33	-0.54
Net Income	-582	-366	-154	-650	378	-349	67	-165	-68	-23	-26	-7.01
Net Income to Common	–	–	–	–	–	–	67	-165	-68	–	–	–
EPS (Basic)(per share)	-6.47	-4.34	-1.94	-8.36	4.97	-5.29	1.23	-3.44	-1.71	-1.89	-5.06	1.97
EPS (Diluted)(per share)	-6.47	-4.34	-1.94	-8.36	4.70	-5.29	1.17	-3.44	-1.71	-1.89	-5.06	1.97
Shares Outstanding (Basic, Weighted)(shares)	90	84	79	78	76	66	54	48	40	12	5.04	3.56
Shares Outstanding (Diluted, Weighted)(shares)	90	84	79	78	80	66	57	48	40	12	5.04	3.56
EBITDA	-645	-447	-203	-649	391	-345	51	-155	-62	-67	-26	-6.59

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3990.0%
Net margin: -3368.7%
Return on equity, FY2025: -30.2%

Financial strength

Current ratio: 17.85
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 219.2%

Valuation

P/E ratio: –
Price to sales: 360.63
Price to book: 2.77
Dividend yield: –